Jane Street
MYGN icon

Jane Street’s Myriad Genetics MYGN Stock Holding History

Jane Street’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,200
Closed -$195K – 9773
2023
Q4 		$195K Sell
10,200
-10,500
-51% -$182K ﹤0.01% 8239
2023
Q3 		$332K Buy
+20,700
New +$394K ﹤0.01% 6918
2023
Q2 		– Sell
-59,900
Closed -$1.39M – 9255
2023
Q1 		$1.39M Buy
59,900
+48,300
+416% +$981K ﹤0.01% 4424
2022
Q4 		$168K Sell
11,600
-20,900
-64% -$389K ﹤0.01% 7789
2022
Q3 		$620K Buy
32,500
+10,400
+47% +$239K ﹤0.01% 6284
2022
Q2 		$402K Sell
22,100
-16,800
-43% -$349K ﹤0.01% 7124
2022
Q1 		$980K Buy
+38,900
New +$996K ﹤0.01% 6181
2021
Q4 		– Sell
-14,000
Closed -$452K – 10573
2021
Q3 		$452K Sell
14,000
-8,800
-39% -$292K ﹤0.01% 7484
2021
Q2 		$697K Buy
22,800
+11,400
+100% +$329K ﹤0.01% 6602
2021
Q1 		$347K Sell
11,400
-19,000
-63% -$539K ﹤0.01% 7465
2020
Q4 		$601K Buy
30,400
+12,700
+72% +$205K ﹤0.01% 5457
2020
Q3 		$231K Sell
17,700
-5,000
-22% -$63.3K ﹤0.01% 6253
2020
Q2 		$257K Buy
+22,700
New +$322K ﹤0.01% 6058
2020
Q1 		– Sell
-20,700
Closed -$564K – 5746
2019
Q4 		$564K Buy
+20,700
New +$569K ﹤0.01% 3551

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street's MYGN Position: Q1 2026 in Review

Jane Street increased its Myriad Genetics (MYGN) stake by 2,110% in Q1 2026, buying an estimated $5.98M and bringing the position to 1,202,531 shares worth $5.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3391.

Jane Street first reported a position in MYGN in Q4 2013 and has held it in 30 quarters since. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Jane Street held 1,202,531 shares of Myriad Genetics worth $5.41M as of Q1 2026.
  • Jane Street bought 1,148,114 Myriad Genetics shares in Q1 2026, an estimated $5.98M.
  • Myriad Genetics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3391 holding.
  • Jane Street first reported a position in Myriad Genetics in Q4 2013 and has held it in 30 quarters since.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.